FDA Clears Roche And Eli Lilly’s Alzheimer’s Blood Test

Live updates

1. 56m ago

   FDA clears first single-biomarker blood test for Alzheimer's

   The US FDA cleared the Elecsys pTau217 blood test, developed by Roche and Eli Lilly, to identify signs of Alzheimer's disease in adults 55 and older experiencing cognitive decline. This tool uses a single biomarker to predict the likelihood of Alzheimer's-related changes rather than providing a formal diagnosis. Labcorp and Quest Diagnostics intend to offer the test to healthcare providers.

   Why it matters

   Traditional Alzheimer's detection often requires more invasive or expensive procedures. This blood test provides a less intrusive method for doctors to screen patients. It marks a shift toward biomarker-based screening for cognitive impairment.

   What is confirmed

   • The FDA cleared the Elecsys pTau217 blood test developed by Roche and Eli Lilly.
   • The test is intended for adults aged 55 and older with cognitive decline.
   • The pTau217 test uses a single biomarker to predict Alzheimer's-related changes.
   • The test does not provide a formal diagnosis of Alzheimer's disease.

   What to watch next

   • Implementation timelines for Labcorp and Quest Diagnostics
   • Clinical outcomes from widespread adoption of the pTau217 test
   Sources used for this update (4)

   1. finance.yahoo.com — Eli Lilly Clears Big Hurdle in Alzheimer's Fight
   2. finance.yahoo.com — FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now
   3. sg.news.yahoo.com — Russia’s overnight drone barrage ignites fires across Ukrainian cities
   4. www.aol.com — FDA clears first single-biomarker blood test for Alzheimer’s: 4 experts weigh in
   confidence 100%
2. 1d ago

   FDA Clears Roche and Eli Lilly's Alzheimer's Blood Test

   The US FDA has cleared the Elecsys pTau217 blood test developed by Roche and Eli Lilly to help detect signs of Alzheimer's disease in adults aged 55 and older with cognitive decline. The test predicts the likelihood of Alzheimer's-related changes using a single biomarker but does not provide a formal diagnosis. Labcorp and Quest Diagnostics plan to offer the test.

   Why it matters

   This clearance is significant for Alzheimer's diagnosis, as it provides a simpler way to assess Alzheimer's-related changes. The test is designed to aid the evaluation process for patients reporting cognitive issues. Alzheimer's disease is a complex condition, and early detection is crucial for effective management.

   What is confirmed

   • The Elecsys pTau217 blood test is intended for adults aged 55 and older who are experiencing cognitive decline.
   • The test predicts the likelihood of Alzheimer's-related changes using a single biomarker.
   • Labcorp and Quest Diagnostics both plan to offer the test.
   • The test secured CE mark certification earlier this year.
   • The FDA clearance was announced on August 24 by Roche.

   What to watch next

   • Health Canada status and Canadian availability of the test
   • Disclosed price of the test
   • Future FDA clearances for similar Alzheimer's blood tests
   Sources used for this update (7)

   1. www.yahoo.com — Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test
   2. www.aha.org — FDA approves new Alzheimer’s blood test
   3. insights.citeline.com — US Alzheimer’s Blood Test Battle Begins With Roche, C2N FDA Clearence
   4. www.benefitsandpensionsmonitor.com — FDA clears blood test to flag Alzheimer's in patients 55 and older
   5. uk.finance.yahoo.com — Eli Lilly Clears Big Hurdle in Alzheimer's Fight
   6. ca.style.yahoo.com — FDA clears two more Alzheimer's blood tests in a single week
   7. www.yahoo.com — FDA Approves Pancreatic Cancer Drug That Could Double Survival Time
   confidence 100%
3. 2d ago

   FDA Clears Roche and Eli Lilly Alzheimer's Blood Test

   The US Food and Drug Administration cleared the Elecsys pTau217 blood test developed by Roche and Eli Lilly to help detect signs of Alzheimer's disease. The test is intended for adults age 55 and older who are experiencing cognitive decline. While the test predicts the likelihood of Alzheimer's-related changes using a single biomarker, it does not provide a formal diagnosis of the brain disorder. The tool is designed to aid the evaluation process for patients reporting cognitive issues.

   Why it matters

   Traditional Alzheimer's detection often requires more invasive or expensive procedures. Moving biomarker testing into primary care could streamline the early identification of the disease. This shift allows clinicians to screen patients more efficiently before pursuing definitive diagnostic paths.

   What is confirmed

   • The FDA cleared a blood test developed by Roche and Eli Lilly to help identify signs of Alzheimer's disease.
   • The test is intended for use in adults age 55 and older with cognitive decline.
   • The specific test name is Elecsys pTau217.
   • The test uses a single biomarker to predict the likelihood of Alzheimer's-related changes.
   • The blood test is not a diagnosis of Alzheimer's disease.

   What to watch next

   • Integration of the test into primary care clinical workflows
   • Clinical data on the test's accuracy compared to traditional diagnostic methods
   Sources used for this update (11)

   1. WSJ — FDA Approves Alzheimer’s Blood Test Developed by Roche and Eli Lilly
   2. Forbes — FDA Clears Roche And Eli Lilly’s Alzheimer’s Blood Test
   3. WashU Medicine — FDA clears blood test to aid evaluation for Alzheimer’s disease
   4. The Washington Post — FDA approves a new blood test to detect signs of Alzheimer’s
   5. The Hill — FDA approves new blood test for Alzheimer’s disease
   6. consent.yahoo.com — FDA clears Roche and Eli Lilly Alzheimer's blood test
   7. theprint.in — US FDA clears Roche-Lilly single-biomarker blood test that helps check for Alzheimer’s-linked changes
   8. www.yahoo.com — Roche, Eli Lilly’s Alzheimer’s blood test gets FDA clearance
   9. www.straitstimes.com — Roche, Eli Lilly’s Alzheimer’s blood test gets US FDA clearance
   10. pharmaphorum.com — FDA greenlights Roche’s biomarker blood test for Alzheimer's
   11. finance.yahoo.com — Roche, Lilly Get US FDA Clearance for Alzheimer's Blood Test
   confidence 100%